Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

This came as part of the continuous regulatory surveillance, where drug samples are picked from sales/distribution points, ...

Provides update on the Company’s transformation and promising portfolio of innovative gene therapy treatments for inherited retinal ...

Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Biotechnology remains a priority sector in India, said Union Minister of State (Independent Charge) for Science and Techno ...

Japan's financial regulator is reportedly set to propose new legislation that would reclassify crypto assets like bitcoin ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Professor Alberto Auricchio, CSO of AAVantgarde and Scientific Director at TIGEM , added,“The results of this study highlight the power of combining cutting-edge vector engineering with deep ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...